Chemical Safety Practices Recommendations Tamoxifen (Soltamox, Novadex)

— •• •					
Exposure Hazards (1)					
Category 1B Danger			Category 1B Danger		
Carcinogenicity			Toxic to Reproduction		
Causes uterine cancer.(2)			Effects fertility and may harm unborn children.(3)		
			May be passed in the milk and harm children.		
Response to Exposure					
Oral		Dermal	Inhalation	Injection	
Rinse mouth; do not induce vomiting. Report to OHS.		Wash skin with soap and water for 15 minutes. Rinse eyes for 15 minutes. Report to OHS.	Leave area; go to clean air. Report to OHS.	Report to OHS.	
Special Precautions	worki	Women pregnant, expecting to become pregnant, or nursing should be extremely cautious when working with Tamoxifen or the feces of animals treated with Tamoxifen. Discard garments as hazardous if contaminated with Tamoxifen.			
Personal Protective Equipment	Gloves (Double glove) (Latex or Nitrile) Skin Protection (Suit or Scrubs or Lab Coat) Eye Protection (Safety-glasses or Goggles) Closed-toe shoes Use N100 respirator if engineering controls are not available.				
Engineering Controls	Tamoxifen powder- Chemical Fume Hood (CFH) Tamoxifen solution- CFH or Biosafety Cabinet (Class II, B2 BSC if aerosolized) Animal waste and bedding until 20 days after last treatment- CFH or Class II, B2 BSC(4)				
Animal Handling	Avoid exposure to animal waste until 20 days after last treatment.				
Bedding Disposal	Dispose of bedding as hazardous material until 20 days after last treatment.				
Work Practices		Empty Tamoxifen containers and unused Tamoxifen must be disposed of as hazardous. Follow LASP SOPs for preparation, handling, dosing, and disposal of Tamoxifen.			
References:					

<u>References:</u>

1. <Tamoxifen MSDS Sigma 10272014.pdf> [Internet]. 2014 [cited 10/27/2014]. Available from: http://www.sigmaaldrich.com/united-states.html.

2. White IN. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Current drug metabolism. 2003;4(3):223-39.

3. NIOSH. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2014. Cincinnati, OH: National Institute for Occupational Safety and Health, DHHS (NIOSH), U.S. Department of Health and Human Services CfDCaP; 2014 September 2014. Report No.: 2014-138 Contract No.: 2014-138.

4. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica; the fate of foreign compounds in biological systems. 1973;3(11):693-709.

Questions or concerns: Please contact EHS, Ted Witte, <u>theodore.witte@mail.nih.gov</u> or 301-846-5860

Reviewed 11/10/2014 These recommendations are not final and may be updated.